Estimating the cost of new drug development: Is it really $802 million?
Estimating the cost of new drug development: Is it really $802 million?
复制标题
DOI：
10.1377/hlthaff.25.2.420
复制
发表时间：
2006-03-01
期刊：
影响因子：
9.7
通讯作者：
Brantner, VV
中科院分区：
文献类型：
--
作者：
Adams, CP;Brantner, VV
本文复制了Joseph DiMasi及其同事的药物开发成本估计（“创新的价格”），使用他们公布的成本估计沿着来自公开数据集的成功率和持续时间的信息。对于1989年至2002年首次进入人体临床试验的药物，该论文估计每种新药的成本为8.68亿美元。然而，我们的估计从大约5亿美元到超过20亿美元不等，这取决于治疗或开发公司。
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be $868 million. However, our estimates vary from around $500 million to more than $2,000 million, depending on the therapy or the developing firm.